Ginkgo Bioworks Holdings (DNA) Amortization of Deferred Charges (2022 - 2026)

Ginkgo Bioworks Holdings' Amortization of Deferred Charges history runs 5 years deep, the most recent figure standing at $7.1 million for Q1 2026.

• Quarterly Amortization of Deferred Charges fell 3.59% year-over-year to $7.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.8 million (changed 0.07% YoY) and the FY2025 annual result came in at $30.1 million, up 7.07% from the prior year.
• Amortization of Deferred Charges was $7.1 million for Q1 2026 at Ginkgo Bioworks Holdings, down from $7.6 million in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $8.3 million in Q3 2023 and bottomed at $3.7 million in Q4 2023.
• A 5-year average of $7.2 million and a median of $7.5 million in 2024 frame the typical range for Amortization of Deferred Charges.
• Annual changes were most pronounced in 2023 — Amortization of Deferred Charges tumbled 48.95% — and 2024, when it soared 103.26%.
• Ginkgo Bioworks Holdings' Amortization of Deferred Charges stood at $7.2 million in 2022, then plunged by 48.95% to $3.7 million in 2023, then surged by 103.26% to $7.5 million in 2024, then gained by 2.1% to $7.6 million in 2025, then slipped by 6.8% to $7.1 million in 2026.
• Business Quant data shows DNA's Amortization of Deferred Charges at $7.1 million in Q1 2026, $7.6 million in Q4 2025, and $7.6 million in Q3 2025.